LGALS3 and Myocardial fibrosis: The inhibition of Gal-3 with MCP in an animal model of myocardial fibrosis results in the attenuation of cardiac function decline and a reduction in collagen deposition in cardiac tissue, associated with decreased expression of Gal-3, TLR4, and MyD88 and lower levels of NF-κB mediated inflammation [64].